Compare TNXP & PERF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | PERF |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | Taiwan |
| Employees | N/A | 353 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.9M | 168.1M |
| IPO Year | 2008 | N/A |
| Metric | TNXP | PERF |
|---|---|---|
| Price | $12.32 | $1.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 567.5K | 61.3K |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,107,000.00 | N/A |
| Revenue This Year | $558.11 | $12.93 |
| Revenue Next Year | $38.29 | $9.44 |
| P/E Ratio | ★ N/A | $26.42 |
| Revenue Growth | ★ 29.85 | N/A |
| 52 Week Low | $10.03 | $1.24 |
| 52 Week High | $69.65 | $2.67 |
| Indicator | TNXP | PERF |
|---|---|---|
| Relative Strength Index (RSI) | 49.93 | 54.11 |
| Support Level | $12.08 | $1.68 |
| Resistance Level | $13.17 | $1.71 |
| Average True Range (ATR) | 0.87 | 0.03 |
| MACD | 0.15 | 0.00 |
| Stochastic Oscillator | 61.08 | 64.29 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions. The company runs a hybrid business model of direct consumer business (B2C business) and enterprise business (B2B business). For B2C businesses, the company offers six mobile apps under the "YouCam" suite, along with one online editing service tool, YouCam Online Editor, featuring AI and AR technologies. For B2B businesses, the company offers AI and AR-powered solutions tailored for the beauty and fashion industry. Geographically, the company has a presence in the United States, Americas-other, France, Japan, and Others. The company generates the majority of its revenue from the United States.